Sabal Trust’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $4.66M | Sell |
5,648
-138
| -2% | -$115K | 0.26% | 68 |
|
|
2024
Q4 | $4.47M | Buy |
5,786
+360
| +7% | +$298K | 0.26% | 69 |
|
|
2024
Q3 | $4.81M | Sell |
5,426
-9
| -0.2% | -$8.09K | 0.26% | 65 |
|
|
2024
Q2 | $4.92M | Buy |
5,435
+22
| +0.4% | +$17.6K | 0.29% | 61 |
|
|
2024
Q1 | $4.21M | Buy |
5,413
+335
| +7% | +$238K | 0.24% | 63 |
|
|
2023
Q4 | $2.96M | Sell |
5,078
-471
| -8% | -$275K | 0.18% | 69 |
|
|
2023
Q3 | $2.98M | Hold |
5,549
| – | – | 0.2% | 64 |
|
|
2023
Q2 | $2.6M | Buy |
5,549
+262
| +5% | +$110K | 0.17% | 68 |
|
|
2023
Q1 | $1.82M | Sell |
5,287
-125
| -2% | -$42.2K | 0.13% | 63 |
|
|
2022
Q4 | $1.98M | Buy |
5,412
+279
| +5% | +$98.9K | 0.13% | 62 |
|
|
2022
Q3 | $1.66M | Buy |
5,133
+108
| +2% | +$34.2K | 0.13% | 62 |
|
|
2022
Q2 | $1.63M | Buy |
5,025
+72
| +1% | +$21.6K | 0.12% | 66 |
|
|
2022
Q1 | $1.42M | Sell |
4,953
-896
| -15% | -$231K | 0.1% | 66 |
|
|
2021
Q4 | $1.62M | Sell |
5,849
-116
| -2% | -$29.4K | 0.1% | 66 |
|
|
2021
Q3 | $1.38M | Buy |
5,965
+500
| +9% | +$123K | 0.1% | 67 |
|
|
2021
Q2 | $1.25M | Sell |
5,465
-45
| -0.8% | -$9.04K | 0.09% | 67 |
|
|
2021
Q1 | $1.03M | Sell |
5,510
-1,514
| -22% | -$296K | 0.08% | 75 |
|
|
2020
Q4 | $1.19M | Sell |
7,024
-26
| -0.4% | -$3.88K | 0.1% | 69 |
|
|
2020
Q3 | $1.04M | Sell |
7,050
-275
| -4% | -$42.6K | 0.09% | 70 |
|
|
2020
Q2 | $1.2M | Sell |
7,325
-300
| -4% | -$46K | 0.11% | 63 |
|
|
2020
Q1 | $1.06M | Buy |
7,625
+606
| +9% | +$83.3K | 0.12% | 60 |
|
|
2019
Q4 | $923K | Sell |
7,019
-492
| -7% | -$57K | 0.07% | 75 |
|
|
2019
Q3 | $840K | Buy |
7,511
+376
| +5% | +$41.9K | 0.07% | 78 |
|
|
2019
Q2 | $790K | Sell |
7,135
-295
| -4% | -$34.7K | 0.07% | 73 |
|
|
2019
Q1 | $964K | Sell |
7,430
-435
| -6% | -$52.9K | 0.09% | 73 |
|
|
2018
Q4 | $911K | Buy |
7,865
+750
| +11% | +$83.8K | 0.09% | 73 |
|
|
2018
Q3 | $764K | Buy |
7,115
+185
| +3% | +$18.5K | 0.07% | 79 |
|
|
2018
Q2 | $591K | Buy |
6,930
+330
| +5% | +$27.1K | 0.06% | 89 |
|
|
2018
Q1 | $511K | Sell |
6,600
-340
| -5% | -$27.4K | 0.05% | 95 |
|
|
2017
Q4 | $586K | Buy |
6,940
+500
| +8% | +$42.5K | 0.06% | 81 |
|
|
2017
Q3 | $551K | Buy |
6,440
+30
| +0.5% | +$2.46K | 0.06% | 82 |
|
|
2017
Q2 | $527K | Buy |
6,410
+10
| +0.2% | +$816 | 0.06% | 81 |
|
|
2017
Q1 | $538K | Buy |
6,400
+75
| +1% | +$6.01K | 0.06% | 80 |
|
|
2016
Q4 | $465K | Sell |
6,325
-1,500
| -19% | -$112K | 0.05% | 82 |
|
|
2016
Q3 | $628K | Sell |
7,825
-300
| -4% | -$24K | 0.07% | 74 |
|
|
2016
Q2 | $640K | Buy |
8,125
+1,712
| +27% | +$129K | 0.07% | 67 |
|
|
2016
Q1 | $462K | Hold |
6,413
| – | – | 0.05% | 77 |
|
|
2015
Q4 | $540K | Hold |
6,413
| – | – | 0.07% | 76 |
|
|
2015
Q3 | $536K | Hold |
6,413
| – | – | 0.07% | 66 |
|
|
2015
Q2 | $535K | Sell |
6,413
-110
| -2% | -$8.38K | 0.07% | 71 |
|
|
2015
Q1 | $474K | Hold |
6,523
| – | – | 0.06% | 73 |
|
|
2014
Q4 | $450K | Hold |
6,523
| – | – | 0.06% | 77 |
|
|
2014
Q3 | $423K | Sell |
6,523
-191
| -3% | -$12.1K | 0.06% | 77 |
|
|
2014
Q2 | $417K | Buy |
6,714
+191
| +3% | +$11.4K | 0.06% | 75 |
|
|
2014
Q1 | $384K | Sell |
6,523
-150
| -2% | -$8.37K | 0.05% | 76 |
|
|
2013
Q4 | $340K | Sell |
6,673
-740
| -10% | -$37.1K | 0.05% | 87 |
|
|
2013
Q3 | $373K | Hold |
7,413
| – | – | 0.06% | 77 |
|
|
2013
Q2 | $364K | Buy |
+7,413
| New | +$403K | 0.06% | 78 |
|
Other funds holding LLY
Sabal Trust's LLY Position: Q1 2025 in Review
Sabal Trust reduced its Eli Lilly (LLY) stake by 2.4% in Q1 2025, selling an estimated $115K and leaving 5,648 shares worth $4.66M. The position accounts for 0.26% of the portfolio, ranked #68.
Sabal Trust first reported a position in LLY in Q2 2013 and has held it in 48 quarters since. The position peaked at $4.92M in Q2 2024. 3,920 funds tracked by Wall St. Rank hold LLY as of Q1 2025.
- Sabal Trust held 5,648 shares of Eli Lilly worth $4.66M as of Q1 2025.
- Sabal Trust sold 138 Eli Lilly shares in Q1 2025, an estimated $115K.
- Eli Lilly made up 0.26% of Sabal Trust's portfolio in Q1 2025, its #68 holding.
- Sabal Trust first reported a position in Eli Lilly in Q2 2013 and has held it in 48 quarters since.
- Sabal Trust's Eli Lilly position peaked at $4.92M in Q2 2024.
- 3,920 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.
Based on Sabal Trust's 13F filing for Q1 2025, filed 23 Apr 2025.